Related Experiment Video
Updated: Jun 5, 2026

09:11
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
[External radiotherapy for hepatocellular carcinoma].
1Service de pneumologie, hôpital Louis-Pradel, hospices civils de Lyon, 28 avenue du Doyen-Jean-Lépine, Bron, France.
Summary
Conformal radiotherapy, once excluded due to toxicity, is now a viable option for hepatocellular carcinoma. Advanced techniques offer improved targeting and tolerance, presenting a potential curative-intent treatment.
Area of Science:
- Hepatobiliary oncology
- Radiation oncology
- Medical physics
Context:
- Hepatocellular carcinoma (HCC) treatment historically excluded radiotherapy due to liver toxicity.
- Conformal radiotherapy represents a significant advancement, enabling dose escalation and combination therapies.
- HCC management is complex, requiring integration of diverse therapeutic modalities.
Purpose:
- To review the role and advancements of conformal radiotherapy in hepatocellular carcinoma treatment.
- To highlight the benefits of conformal radiotherapy, particularly in cirrhotic patients.
- To discuss technical developments enhancing radiation delivery for HCC.
Summary:
- Conformal radiotherapy is increasingly recognized for HCC, offering non-invasiveness, broad applicability, and a favorable safety profile, even in patients with cirrhosis.
- Technical innovations like respiratory gating, intensity-modulated radiotherapy, and stereotactic techniques improve radiation focalization and precision.
- High response rates suggest conformal radiotherapy could be a curative-intent option for HCC, comparable to surgery or percutaneous ablation.
Impact:
- Conformal radiotherapy offers a promising, well-tolerated treatment option for hepatocellular carcinoma, especially in challenging patient populations.
- Optimized radiation delivery techniques enhance treatment efficacy and safety for HCC.
- Further randomized trials are needed to establish the definitive role of radiotherapy within the HCC therapeutic algorithm.

